ADDRENEX PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.addrenex.com
A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00779181
CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
Phase 3
Completed
- Conditions
- ADHD
- Interventions
- Drug: CLONICEL (clonidine HCl sustained release)Drug: Placebo
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2010-04-09
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT00641329
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- Addrenex Pharmaceuticals, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT00556959
© Copyright 2025. All Rights Reserved by MedPath